InsiderTrades

Form 4 for DNLI Denali Therapeutics Inc.

Accepted 2023-01-05 00:00:00 ET · period of report 2023-01-03 · accession 0001209191-23-002181 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2023-01-05 2023-01-03 DNLI Schuth Alexander O. COFO, Sec A - Grant $0.00 +41.1K 157.6K +35% $0
D 2023-01-05 2023-01-04 DNLI Schuth Alexander O. COFO, Sec S - Sale $28.70 -2,912 149.8K -2% -$83.6K
D 2023-01-05 2023-01-03 DNLI Schuth Alexander O. COFO, Sec A - Grant $0.00 +123.4K 123.4K New $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2023-01-03 A A 41,120 $0.00 157,578 D — — (F1) Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 25% of the RSUs shall vest on January 3, 2024 (the "Vesting Commencement Date") and an additional 25% of the RSUs shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. (F2) Includes 138,192 RSUs.
2 Common Common Stock 2023-01-04 S D 2,912 $28.70 149,828 D — — (F4) The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $28.48 to $28.96 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. (F2) Includes 138,192 RSUs. (F5) Reflects the issuance of shares to The Schuth Family Trust U/A DTD 06/05/2017 in connection with the vesting of 7,750 RSUs held by the Reporting Person.
3 Derivative Stock Option (right to buy) 2023-01-03 A A 123,360 $0.00 123,360 D $27.63 · — to 2033-01-02 123,360 Common Stock (F7) 25% of the shares subject to the option shall vest on January 3, 2024, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date.